BACKGROUND: Vitamin D compounds are important modulators of cellular proliferation and differentiation, with potential utility as anticancer drugs. 1,24(S)-Dihydroxyvitamin D2 [1,24(OH)2D2] is a naturally occurring active vitamin D compound with low calcemic activity. MATERIALS AND METHODS: We evaluated the growth inhibitory effects of 1,24(OH)2D2 on LNCaP prostate cancer and MCF-7 breast cancer cells. 1,24(OH)2D2 was evaluated alone and in paired combination with nine chemotherapeutic agents. Drug interactions were analyzed using the median-effect/isobologram method. Combination index values were used to characterize the interactions as synergistic, additive, or antagonistic. RESULTS: In MCF-7 cells, 1,24(OH)2D2 produced synergistic effects with doxonrubicin and cisplatin and additive effects with busulfan, etoposide, tamaxifen, 5-fluorouracil and carboplatin. In LNCaP cells, 1,24(OH)2D2 produced a synergistic effect with carboplatin and additive effects with doxorubicin, busulfan, paclitaxel and etoposide. CONCLUSION: We conclude that 1,24(OH)2D2 may have therapeutic value in the treatment of prostate and breast cancers, alone or in combination with chemotherapeutic agents.
BACKGROUND:Vitamin D compounds are important modulators of cellular proliferation and differentiation, with potential utility as anticancer drugs. 1,24(S)-Dihydroxyvitamin D2 [1,24(OH)2D2] is a naturally occurring active vitamin D compound with low calcemic activity. MATERIALS AND METHODS: We evaluated the growth inhibitory effects of 1,24(OH)2D2 on LNCaP prostate cancer and MCF-7 breast cancer cells. 1,24(OH)2D2 was evaluated alone and in paired combination with nine chemotherapeutic agents. Drug interactions were analyzed using the median-effect/isobologram method. Combination index values were used to characterize the interactions as synergistic, additive, or antagonistic. RESULTS: In MCF-7 cells, 1,24(OH)2D2 produced synergistic effects with doxonrubicin and cisplatin and additive effects with busulfan, etoposide, tamaxifen, 5-fluorouracil and carboplatin. In LNCaP cells, 1,24(OH)2D2 produced a synergistic effect with carboplatin and additive effects with doxorubicin, busulfan, paclitaxel and etoposide. CONCLUSION: We conclude that 1,24(OH)2D2 may have therapeutic value in the treatment of prostate and breast cancers, alone or in combination with chemotherapeutic agents.
Authors: Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey Journal: J Oncol Pharm Pract Date: 2014-07-01 Impact factor: 1.809
Authors: Ahmed El-Serafi; Rui He; Wenyi Zheng; Fadwa Benkossou; Sandra Oerther; Ying Zhao; Karin Mellgren; Britt Gustafsson; Carsten Heilmann; Jukka Kanerva; Kourosh Lotfi; Jacek Toporski; Mikael Sundin; Martin Höglund; Jonas Mattsson; Ibrahim El-Serafi; Moustapha Hassan Journal: Bone Marrow Transplant Date: 2020-10-21 Impact factor: 5.483
Authors: Samuel Seoane; Maria A Bermudez; Juan Sendon-Lago; Anxo Martinez-Ordoñez; Soraya Abdul-Hadi; Miguel Maestro; Antonio Mouriño; Roman Perez-Fernandez Journal: Cancers (Basel) Date: 2013-12-27 Impact factor: 6.639
Authors: Zaid H Maayah; Ti Zhang; Marcus Laird Forrest; Samaa Alrushaid; Michael R Doschak; Neal M Davies; Ayman O S El-Kadi Journal: Pharmaceutics Date: 2018-09-04 Impact factor: 6.321